Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $55.0, a high estimate of $71.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 1.63% from the previous average price target of $54.12.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Halozyme Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Halozyme Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Halozyme Therapeutics analyst ratings.

All You Need to Know About Halozyme Therapeutics

Key Indicators: Halozyme Therapeutics's Financial Health

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Halozyme Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 20.81%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Halozyme Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 39.22%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Halozyme Therapeutics's ROE excels beyond industry benchmarks, reaching 58.73%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Halozyme Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.3% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Halozyme Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 8.44. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: Simplified

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.